Effectiveness of Vaccine on Outcome in SARS-COV-2 Hospitalised Patients
DOI:
https://doi.org/10.37506/6yhb3k34Keywords:
covid-19, india, sars-cov-2, vaccination, patients.Abstract
BackgroundVaccination is considered a one of the most efficient strategy for prevention and control of COVID-19 pandemic in future. The vaccination development globally by top pharmaceutical and pharmacy companies have shown positive impact in providing active immunity against disease, also it has an impact in reducing the severity of the disease.
Objective: To analyze the vaccination status with outcome of SARS-CoV 2 admitted patients. To assess the impact of any co-morbidities on SARS-CoV-2 outcome in these patients.
Design: An observational retrospective study was conducted in our hospital in northern Indian from 1st April 2021 to 31st March 2022.
Results: The analysis was of 365 patients who satisfied our inclusion and exclusion criteria were included in the study. 132 patients were vaccinated in which 38 received one dose and 69 received second of COVISHEILD and 22 received one dose and 3 received second of COVAXIN while 233 patients did not receive vaccination. The mean length of ICU stay among vaccinated patients was 4.27±3.2 days compared to non-vaccinated patients 11.40±12.14 days (p=0.001). Mortality was higher in non-vaccinated group (68 patients) compared to vaccinated group (14 patients).
Conclusion: Duration of stay in hospital, oxygen required, ventilator required and death were significantly less in vaccinated patients as compare to non- vaccinated patients.
References
Hu B, Guo H, Zhou P, Shi-Li Z. Characteristics of SARS-COV-2 andCOVID-19. Nat Rev Microbial 2021; 19:141-54. (PMID 33024307)
Sean Wei Xiang Ong, Calvin J Chiew, Li Wei Ang, Tze-Minn Mak, Lin Cui, Matthias Paul H S Toh, et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clinical Infectious Diseases. 2021; 20(20):1-9. (PMID 34423834)
Desai A, Desai P, Mehta J, Sachora W, Bharti N, Patel T, et al. Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement and mortality outcome in a tertiary care centre. International Journal of Infectious Diseases. 2021 (113):282-87. (PMID 34688949)
Zhao, S, Lin, Q, Ran, J, Zhao, S, Lin, Q, Ran, J., Musa, S. S., Yang, G, Wang, W, Lou, Y, Gao, D, Yang, L., He, D., and Wang, M. H. (2020) Preliminary estimation of the basic reproduction number of novel coronavirus (2019‐nCoV) in China, from 2019 to 2020: A data‐driven analysis in the early phase of the outbreak. Int. J. Infect. 92, 214–217.
Machingaidze S., Wiysonge CS., Understanding COVID-19 vaccine hesitancy.Nat Med. 2021; 27: 1338-1339
WHO Achieving 70% COVID-19 immunization coverage by mid-2022.Date: Dec 23, 2021. Date accessed: February 4, 2022
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis, and practical considerations. Diabetes MetabSyndrClin Res Rev. 2020;14(4):303–10 [Accessed April 18, 2020.
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1–30, 2020. Centers for Disease Control and Prevention: MMWR. 2020; 69(15):458–464.
Huang C, Wang Y, et. al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.
Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020 Jun 01;318(6):F1454-F1462
Taquet M, Geddes JR, et.al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 May;8(5):416-427.
Ministry of Health and Family Welfare, Government of India. COVID-19 vaccines operational guidelines. Updated December 28, 2020. [Internet]. [cited 2021 Jul 14].
Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. Journal of the American Medical Association Internal Medicine. 2020(180)10: 1345-55. (PMID 32667669)
Balanchandran S Moni, M, Sathyapalan D, Varghese P, Jose M, Murugan M, et al. A comparison of clinical outcomes between vaccinated and vaccine –navie patients of COVID-19, in four tertiary care hospitals of Kerala, South India .Clinical and Epidemiology and Global Health. 2022 :1-5. (PMID 35075439)
Williamson J.E, Walker A, Bhaskaran K, Bacon S, Bates C, Mortan E.C, CurtisJ.H, et al. Factors associated with COVID-19 related death using open safely. 2020 ;( 584):430-43.
Niessen F.A, Knol M.J, et.al. Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands. Journal Elsevier. com. 2022 ;( 40):5044-49.
Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-COV-2 among patients in the Oxford Royal College of General Pracitioners Research and Surveillance Centre primary care network.2020;(20):1034-042.
Alsaffar A W, Alwesaibi A, et. al. The Effectiveness of COVID-19 vaccines in improving the outcomes of hospitalized COVID-19 patients. Cureus publishing beyond open access. 2022(1)14:1-15 (PMID 35103227)
Bhatnagar T, Chaudhuri S, et.al. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi centric hospital- based case- control study. International J Infect Dis. 2022(122): 693-702.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en